Background Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic colorectal cancer patients, but its mechanisms are unknown. We recently found, using data of the randomized phase 3 CAIRO3 study, that SMI loss was related with shorter time to disease progression and overall survival during first-line maintenance treatment with capecitabine + bevacizumab (CAP-B) or observation and during more intensive capecitabine + oxaliplatin + bevacizumab (CAPOX-B) reintroduction treatment. As a potential risk factor for reduced survival, we explored whether sarcopenia and SMI loss were associated with dose-limiting toxicities (DLTs) during CAP-B and CAPOX-B. Methods Sarcopenia status and SMI loss were assessed by using consecutive computed tomography scans. DLTs were defined as any dose delay/reduction/discontinuation of systemic treatment because of reported CTCAE (version 3.0) toxicities at the start or during treatment. Poisson regression models were used to study whether sarcopenia and body mass index (BMI) at the start of treatment and SMI and BMI loss during treatment were associated with DLTs. Results One hundred eighty-two patients (mean age 63.0 ± 8.8 years, 37% female) received CAP-B, and 232 patients (mean age 63.0 ± 9.0 years, 34% female) received CAPOX-B. At the start of CAP-B and CAPOX-B, 54% and 46% of patients were sarcopenic, respectively. Mean BMI was lower in sarcopenic patients, although patients were on average still overweight (sarcopenic vs. non-sarcopenic at the start of CAP-B 25.0 ± 3.9 vs. 26.7 ± 4.1 and CAPOX-B 25.8 ± 3.8 vs. 27.1 ± 3.8 kg/m 2 ).
Introduction
Muscle mass loss in cancer patients, including metastatic colorectal cancer (mCRC), is common and not exclusive to underweight patients.
1,2 Muscle mass loss and low muscle mass (sarcopenia) are associated with poor treatment outcomes. A recent meta-analysis found that 19-71% of mCRC patients suffer from sarcopenia and that sarcopenia was associated with poor overall survival and increased treatmentrelated toxicities. 3 In several studies, the loss of muscle mass was also associated with reduced survival.
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The mechanisms by which muscle depletion links to poor survival are unknown. It is hypothesized that the increased treatment-related toxicities risk in these patients may be a major contributor.
3 Excess toxicities could lead to more frequent dose reductions, dose delays, and treatment discontinuations [i.e. dose-limiting toxicities (DLTs)]. DLTs may lead to a reduced dose intensity (i.e. dose of chemotherapy delivered per unit of time) and dose density (i.e. time of intervals between dose administration of chemotherapy), which may be important determinants for the effects of systemic treatment on survival. 7, 8 Low muscle mass may be related to excess toxicities due to an increased fragility or a pharmacokinetic effect. 9, 10 Currently, systemic treatment is dosed on the patients' weight and height [body surface area (BSA)] and does not incorporate body composition. In sarcopenic patients, altered distribution parameters, due to lower muscularity for hydrophilic drugs such as capecitabine, could lead to higher drug concentrations (in a shorter amount of time) and subsequent more frequent toxicities.
9,10
Several studies in (m)CRC patients found an association between low muscle mass and an increased toxicity risk during systemic treatment. [11] [12] [13] [14] However, most of these studies were limited in sample size or did not investigate the occurrence of subsequent dose reductions, delays, and discontinuations, which may have more impact on survival than toxicity in general. Although muscle mass is influenced by type of cancer and/or treatment and the occurrence of toxicities depends on the type of drugs and their intensity, 3 most studies used only one time point to assess muscle mass during the course of the disease and were heterogeneous in terms of drugs administered. Here, as a potential risk factor for reduced survival in mCRC patients, we investigate whether sarcopenia at the start of treatment and longitudinal muscle mass loss during treatment are associated with increased risk of DLTs and other treatment-related toxicities during capecitabine + bevacizumab (CAP-B) and subsequent capecitabine + oxaliplatin + bevacizumab (CAPOX-B). We used data of the randomized phase 3 mCRC CAIRO3 study, 15 in which we previously found that muscle loss during these subsequent treatment phases was related to early disease progression and reduced overall survival.
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Materials and methods
Study population
In CAIRO3, mCRC patients with stable disease or better after first-line systemic treatment with 6 cycles CAPOX-B were randomized to CAP-B maintenance treatment or observation. Eligible patients were aged ≥18 years, had histological proof of CRC, had World Health Organization performance status ≤1, and received no previous systemic treatment for mCRC. After first progression on CAP-B or observation (PD1), patients received CAPOX-B reintroduction treatment or, if not feasible, any other treatment until second progression (PD2). Patients were assessed for disease status by computed tomography (CT) scans every 9 weeks according to RECIST criteria 17 or at any time when disease progression was suspected based on clinical symptoms. Data on a patient's height, body weight, and the occurrence of DLTs were available for the two consecutive treatment phases within CAIRO3 (i.e. CAP-B and CAPOX-B reintroduction). Here, we selected patients with an available abdominal CT scan at the start and end of these regimens. Ethical approval for CAIRO3 was acquired by the Medical Ethics Committee of Nijmegen, The Netherlands. The CAIRO3 trial protocol was registered at ClinicalTrials.gov (NCT00442637).
Skeletal muscle mass analysis
Computed tomography scans were analysed for muscle mass by a trained analyst and a software tool (Slice-o-Matic, version 5.0; Tomovision). Detailed information on muscle analysis is reported elsewhere. 2 In short, we used cross-sectional evaluation of single slices with the third vertebral level (L3) as a landmark, which highly correlates with total body muscle mass. 18 Before selecting the L3 slice, a rigid fusion method was used to rotate and fuse repeated CT scans to reduce measurement errors due to variation in the positioning of patients during consecutive CT scans over time. We used preestablished thresholds for Hounsfield units (À29 to 150 HU) to quantify the muscle compartments (i.e. psoas, paraspinal, and abdominal wall muscles). Cross-sectional areas (cm 2 ) were computed for each image and used to calculate the skeletal muscle index (SMI): 
Assessment of toxicities
Dose-limiting toxicities were defined as any dose delay (>3 days), reduction, or discontinuation of systemic treatment because of reported toxicities. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (CTCAE), version 3.0.
Recommendations on dose adjustments were described in the CAIRO3 study protocol (Table S1 ). A dose delay was recommended in case of grade ≥2 non-haematologic toxicity, and treatment administration was not resumed before improvement to grade 1. A dose reduction was recommended when grade ≥3 toxicity occurred or in case of grade ≥2 neuropathy. Specific dose adaptations depended on both the type of agent and the specific toxicity. Dose reductions for bevacizumab were not applied. Doses reduced for toxicity were not re-escalated. Treatment was discontinued after the occurrence of progression of disease, unacceptable toxicities that prevented the further safe administration of treatment, if the patient refused to receive further treatment or when another treatment was indicated (e.g. metastasectomy, another primary tumour, and start radiation therapy).
Statistical analysis
Poisson regression models were used to estimate the relative risks (RRs) for the association between sarcopenia, SMI loss, and the presence of DLTs or other toxicities during treatment. 20 Each treatment period was analysed separately for the association of any DLT (0 vs. ≥1) or any treatment-related toxicity (0 vs. ≥1) with sarcopenia (yes/no) SMI loss [>2% loss vs. ≤2% SMI loss (i.e. loss vs. stable/gain)]. All models were adjusted for the following, empirically selected, potential confounders: age (continuously), sex (male/female), primary tumour resection (yes/no), and dose reduction during initial (pre-randomization) CAPOX-B treatment (yes/no). During CAPOX-B reintroduction treatment, we additionally adjusted for treatment received after CAIRO3 randomization (maintenance CAP-B vs. observation). To correct for possible overdispersion (more variation in the outcome than is expected by the model, which can result in an underestimation of the standard errors of model parameters), we used robust standard errors. 20 As a secondary analysis, we investigated the association between BMI (normal weight/overweight/obese) at the start of treatment and BMI loss during treatment with DLTs or other toxicities. BMI loss was continuously included in the analysis due to the small number of patients who lost >2% BMI (i.e. n = 10 during CAP-B and n = 28 during CAPOX-B). All P-values were twosided, and the level of significance was considered at P < 0.05. For all statistical analyses, we used SPSS version 21.
Results
Based on the availability of CT scans or BMI measures, 182 patients who received CAP-B and 232 patients who received CAPOX-B were included. Figure 1 displays reasons for missing or non-evaluable CT scans. During both regimens, baseline characteristics of patients with available CT scans were comparable with patients without available CT scans (P > 0.05). Sarcopenia was observed in 54% and 46% of patients at the start of CAP-B and CAPOX-B, respectively ( Table 1) . Sarcopenic patients were less frequently obese compared with non-sarcopenic patients (at the start of CAP-B 11% vs. 22% and CAPOX-B 9% vs. 21%, respectively). Mean BMI was lower in sarcopenic patients, although patients were on average still overweight (sarcopenic vs. non-sarcopenic patients at the start of CAP-B 25.0 ± 3.9 vs. 26.7 ± 4.1 and at the start of CAPOX-B 25.8 ± 3.8 vs. 27.1 ± 3.8 kg/m 2 ).
Detailed information on muscle mass and body weight changes during CAIRO3 treatments were reported elsewhere. 2, 16 In short, during CAP-B, 28% of patients lost >2% SMI, and 66% of patients lost >2% SMI during CAPOX-B.
Dose-limiting toxicities during treatment
During both regimens, DLTs were frequently observed. Overall, more than half of patients experienced ≥1 DLTs ( Muscle loss and dose-limiting toxicities in mCRC patients 
Toxicities during treatment
During both regimens, grade ≥2 and ≥3 toxicities occurred frequently ( Table 2) .
Discussion
In this large longitudinal study, we evaluated the association between sarcopenia and SMI loss and the occurrence of DLTs during two consecutive palliative treatment regimens in mCRC patients. We found that, in patients with good tolerance of 6 cycles initial CAPOX-B treatment, >2% SMI loss during subsequent less intensive CAP-B treatment was significantly associated with an increased risk of DLTs. Furthermore, patients with sarcopenia at the start of CAPOX-B reintroduction treatment or with >2% SMI loss during previous CAP-B treatment or observation more frequently received a dose reduction at the start of CAPOX-B reintroduction. Finally, during CAP-B, patients with >2% SMI loss had a significantly increased risk of grade ≥3 toxicities. Our study is the first on this topic that uses both crosssectional SMI and longitudinal SMI change during treatment to investigate the relation between SMI loss and DLTs during two consecutive regimens. Another important strength of this study is that we used data of a large randomized phase 3 trial, implying high-quality data inherent to data collection in trials, with standardized toxicity assessments and protocol recommendations on dose adjustments. Our findings that Muscle loss and dose-limiting toxicities in mCRC patients sarcopenia at the start of treatment was associated with an increased toxicity risk are in line with previous, mostly small, and cross-sectional studies.
11-14 The increased risk in these studies ranged from a factor 1.5 to 13.5, mainly depending on type of treatment and the definition of sarcopenia used [e.g. some studies determined cut-off points for the dose of systemic treatment/kg lean body mass (LBM) and found that patients who received a dosage above the cut-off points have an increased toxicity risk toxicities]. Our data additionally show that SMI loss over time is associated with an increased toxicity risk. Hence, our data support the observation that the loss of muscle mass is associated with increased DLTs and may contribute to the observed reduced survival in these patients. In contrast to SMI loss, BMI (loss) was not associated with an increased risk of DLTs, although obese compared with normal weight patients had a lower risk of grade ≥2 toxicities during CAP-B, which might be explained by their on average higher SMI, 21 and although patients who lost BMI (i.e. both fat and muscle mass loss) during CAPOX-B had an increased risk of grade ≥3 toxicities. We conclude that BMI is not an appropriate tool to identify patients at risk of poor outcome and may wrongly reassure clinicians about patients' nutritional status. Indeed, at the start of both regimens, 54% of patients were sarcopenic, despite the fact that these patients were on average overweight. In mCRC patients, CT scans are routinely performed for diagnosis and treatment evaluation and therefore readily available for body composition analysis. Therefore, muscle mass analysis using routine CT scans is a potential tool to identify patients at risk for poor outcome, without additional costs or patient burden. We did not find an association between sarcopenia and toxicities during CAP-B. A possible explanation is that in CAIRO3, patients with intolerance for initial CAPOX-B (i.e. severe toxicity that prevented its further safe administration) were excluded from participation.
Sarcopenia at the start of CAPOX-B and SMI loss during previous CAP-B were associated with dose reductions at the start of CAPOX-B. Of patients who received a dose reduction, 70% had received a dose reduction during previous treatments (i.e. initial CAPOX-B or CAP-B), whereas 30% had not. Of these 30%, reasons for dose reductions were not specified. Sarcopenia and SMI loss are associated with poor physical functioning, increased fatigue, and reduced quality of life. 22 We hypothesize that patients with SMI loss present in less fit condition, which may cause physicians to initiate dose reductions at the start of treatment in order to prevent toxicity. A potential method to reduce DLTs in sarcopenic patients is to adjust chemotherapy dosing to body composition, as most anticancer agents distribute and metabolize within the fat-free mass or LBM.
10,23 Sarcopenic patients may have altered pharmacokinetic parameters, including area under the time concentration curve and clearance. 23 Currently, doses of systemic treatment are determined by BSA, which is too simplified to describe body composition. Indeed, several studies in patients with cancer showed that LBM has a low correlation with BSA, 13, 23 especially in obese patients.
9
One study in CRC patients who received 5-fluorouracil intravenously found that low LBM was associated with a decrease in distribution volume and clearance. 24 Two studies investigated the relation between BSA dosed capecitabine and oxaliplatin normalized to LBM and found that treatment concentrations above the cut-off points were associated with severe toxicity, including grade ≥3 toxicities for capecitabine and dose-limiting neuropathy for oxaliplatin.
12,13 Even more, in both studies, negligible toxicity was observed in patients who received doses below the cut-off points, which may imply that they may benefit from higher doses. Normalizing chemotherapy to LBM may be a potent tool to individualize chemotherapy treatment and to prevent toxicity. This concept awaits verification, and the first prospective feasibility study is initiated in patients with metastatic lung cancer.
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Another potential tool to increase chemotherapeutic tolerance is muscle mass preservation. In advanced cancer patients, muscle loss is a multifactorial syndrome in which a reduced nutritional intake, metabolic changes (due to the tumour and treatment), often combined with low physical activity levels, lead to alterations in body composition and eventually to cancer cachexia. 26 Muscle mass preservation during later stages of advanced cancer, after (extensive) weight loss has occurred, is difficult as the progressive metabolic derangements that occur during cancer (cachexia) may no longer be reversible, at least not by the conventional interventions such as nutritional support. 37 and lung cancer patients (n = 90) 38 receiving chemotherapy with paclitaxel and/or platinum found a significant reduction in neuropathy incidence after fish oil supplementation, although in the lung cancer trial, this was not the primary endpoint. These results have now led to several ongoing randomized trials to study the effects of muscle mass preservation on oncologic outcomes, 35, 39 including a randomized trial that examines the efficacy of resistance exercise and protein supplementation on lean mass to reduce DLTs in patients with (non-metastatic) colon cancer (ClinicalTrials.gov number: NCT03291951). Furthermore, it was previously shown that high-aged patients have an increased risk of toxicities and of being sarcopenic. However, whether older patients have a different risk of experiencing toxicities due to sarcopenia/SMI change compared with younger patients is unknown. Because of the low number of patients aged 70 years or older in this study (n = 45 during CAP-B and n = 52 during CAPOX-B), we could not analyse the effects of sarcopenia or SMI loss on DLT and toxicity risk in high-aged patients in this study. However, due to the increasing number of elderly patients with cancer, future research on this topic seems important, including studies that investigate the effects of interventions that aim to increase muscle mass in elderly cancer populations.
We are aware of some limitations of the current research. Firstly, patients were excluded if CT scans were unavailable, for example, because of treatment discontinuation or disease progression. This may have resulted in a selection (bias) and an underestimation of the observed effect (i.e. when excluded patients with poor prognosis had an increased risk of DLTs). However, baseline characteristics of patients with and without evaluable CT scans were comparable, and we adjusted for potential confounders in our analysis. Secondly, data on lifestyle measures and nutritional intake were not available in CAIRO3, and both may have impact on SMI loss and toxicity risk. Thirdly, because this is an observational analysis, we cannot draw conclusions on the causal relationship between SMI loss and toxicity, and we cannot exclude residual confounding.
Conclusions
In mCRC patients during palliative systemic treatment, sarcopenia and SMI loss are associated with an increased risk of DLTs, which may contribute to the observed worse survival in this group of patients. BMI was not associated with DLTs and could not accurately detect sarcopenia or SMI loss. Muscle mass analysis by using routine CT scans has the potential to identify patients at risk of poor outcomes. Prospective studies should reveal whether normalizing chemotherapeutic doses to muscle mass or preservation of muscle mass (by exercise and nutritional interventions) increases chemotherapeutic tolerance and improves survival.
